Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan

International Journal of Hematology

Volumn 76, Issue 5, 2002, Pages 411-419

  Tobinai, Kensei ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

B cell lymphoma; CD20; Chimeric antibody; Monoclonal antibody therapy; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB;

B CELL LYMPHOMA; CLINICAL TRIAL; HUMAN; IMMUNOLOGY; JAPAN; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; JAPAN; LYMPHOMA, B-CELL;

EID: 0038819920     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/BF02982806     Document Type: Article

References (29)

1. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas.Semin Oncol. 1993; 20(suppl 5): 75–88.
2. Bierman PJ, Vose JM, Anderson JR, et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma.J Clin Oncol. 1997; 15: 445–450. DOI: 10.1200/JCO.1997.15.2.445
3. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.Blood. 1994; 83: 435–445.
4. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.Blood. 1994; 84: 2457–2466.
5. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.Nat Med. 2000; 6: 443–446. DOI: 10.1038/74704
6. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8 results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma.J Clin Oncol. 1997; 15: 3266–3274. DOI: 10.1200/JCO.1997.15.10.3266
7. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rit-uximab) anti-CD20 antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma.Blood. 1997; 90: 2188–2195.
8. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998; 16: 2825–2833. DOI: 10.1200/JCO.1998.16.8.2825
9. Tobinai K, Kobayashi Y, Narabayashi M et al. Feasibility and phar-macokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma.Ann Oncol. 1998; 9: 527–534. DOI: 10.1023/A:1008265313133
10. Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.Ann Oncol. 2002; 13: 928–943. DOI: 10.1093/annonc/mdf155
11. Tobinai K. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin’s lymphoma in Japan.Cancer Chemother Phamacol. 2001; 48(suppl 1): S85-S90. DOI: 10.1007/s002800100313
12. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.Blood. 1994; 84: 1361–1392.
13. Igarashi T, Ohtsu T, Fujii H, et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab.Int J Hematol. 2001; 73: 213–221. DOI: 10.1007/BF02981940
14. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.Blood. 1998; 92: 1927–1932.
15. Foran JM, Rohatiner AZS, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.J Clin Oncol. 2000; 18: 317–324. DOI: 10.1200/JCO.2000.18.2.317
16. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment.J Clin Oncol. 2000; 18: 3135–3143. DOI: 10.1200/JCO.2000.18.17.3135
17. Schmitz K, Brugger W,Weiss B, Kaiserling E, Kanz L. Clonal selection of CD20-negative non-Hodgkin’s lymphoma cells after treatment with anti-CD20 antibody rituximab [letter].Br J Haematol. 1999; 106: 571–572. DOI: 10.1046/j.1365-2141.1999.01608.x
18. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.Clin Cancer Res. 1999; 5: 611–615.
19. Micallef INM, Kirk A, Norton A, Foran JM, Rohatiner AZS, Lister TA. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma [letter].Blood. 1999; 93: 2427–2428.
20. Kinoshita T, Nagai H, Murate T, Saito H. CD20-negative relapse in B-cell lymphoma after treatment with rituximab [letter].J Clin Oncol. 1998; 16: 3916. DOI: 10.1200/JCO.1998.16.12.3916
21. Igarashi T, Itoh K, Kobayashi Y, et al. Phase II and pharmacokinetic study of rituximab with eight weekly infusions in relapsed aggressive B-cell non-Hodgkin’s lymphoma (B-NHL).Proc Am Soc Clin Oncol. 2002; 21: 286a.
22. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lym-phomas.J Clin Oncol. 1999; 17: 1244–1253. DOI: 10.1200/JCO.1999.17.4.1244
23. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.J Clin Oncol. 1999; 17: 268–276. DOI: 10.1200/JCO.1999.17.1.268
24. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma.J Clin Oncol. 2001; 19: 389–397. DOI: 10.1200/JCO.2001.19.2.389
25. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rit- uximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med. 2002; 346: 235–242. DOI: 10.1056/NEJMoa011795
26. Witzig TE, White CA,Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma.J Clin Oncol. 1999; 17: 3793–3803. DOI: 10.1200/JCO.1999.17.12.3793
27. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioim-munotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma.J Clin Oncol. 2002; 20: 2453–2463. DOI: 10.1200/JCO.2002.11.076
28. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas.J Clin Oncol. 2001; 19: 3918–3928. DOI: 10.1200/JCO.2001.19.19.3918
29. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy cell leukemia.N Engl J Med. 2001; 345: 241–247. DOI: 10.1056/NEJM200107263450402